N MR 2 -Based Drug Discovery Pipeline Presented on the Oncogenic Protein KRAS
Journal of the American Chemical Society · 2025
DOI: 10.1021/jacs.4c16762 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, 2025. Verfasst von Matthias Bütikofer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Vienna, Josef-Holaubek-Platz 2, 2F 353, Vienna, A-1090, Austria. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Drug Discovery, Nuclear Magnetic Resonance, Biomolecular. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung, Swiss Cancer Research Foundation.
Abstract (Originalsprache)
Fragment-based drug discovery has emerged as a powerful approach for developing therapeutics against challenging targets, including the GTPase KRAS. Here, we report an NMR-based screening campaign employing state-of-the-art techniques to evaluate a library of 890 fragments against the oncogenic KRAS G12V mutant bound to GMP-PNP. Further HSQC titration experiments identified hits with low millimolar affinities binding within the SI/SII switch region, which forms the binding interface for the effector proteins. To elucidate the binding modes, we applied NMR molecular replacement (NMR2) structure calculations, bypassing the need for a conventional protein resonance assignment. Traditionally, NMR2 relies on isotope-filtered nuclear Overhauser effect spectroscopy experiments requiring double-labeled [13C,15N]-protein. We introduce a cost-efficient alternative using a relaxation-based filter that eliminates isotope labeling while preserving structural accuracy. Validation against standard isotopically labeled workflows confirmed the equivalence of the derived protein-ligand structures. This approach enabled the determination of 12 NMR2 KRAS-fragment complex structures, providing critical insights into structure-activity relationships to guide ligand optimization. These results demonstrate the streamlined integration of NMR2 into a fragment-based drug discovery pipeline composed of screening, binding characterization, and rapid structural elucidation with or without isotopic labeling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, University of Vienna, Josef-Holaubek-Platz 2, 2F 353, Vienna, A-1090, Austria.
- Institute for Molecular Physical Science, Vladimir Prelog Weg 2, Zürich, 8093, Switzerland.
- NexMR AG, Wiesenstrasse 10A, Schlieren, 8952, Switzerland.
- St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee, 38105, United States.
ORCID-Profile: Matthias Bütikofer, Felix Torres, Harindranath Kadavath, Nina Gämperli, Nicolas Coudevylle, Roland Riek, Julien Orts
Förderung
- Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung
- Swiss Cancer Research Foundation
Zitieren
APA
Bütikofer, M., Torres, F., Kadavath, H., Gämperli, N., Abi Saad, M. J., Zindel, D., Coudevylle, N., Riek, R., & Orts, J. (2025). N MR 2 -Based Drug Discovery Pipeline Presented on the Oncogenic Protein KRAS. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.4c16762
Vancouver
Bütikofer M, Torres F, Kadavath H, Gämperli N, Abi Saad MJ, Zindel D, et al. N MR 2 -Based Drug Discovery Pipeline Presented on the Oncogenic Protein KRAS. Journal of the American Chemical Society. 2025. doi:10.1021/jacs.4c16762
BibTeX
@article{Btikofer2025,
author = {Bütikofer, Matthias and Torres, Felix and Kadavath, Harindranath and Gämperli, Nina and Abi Saad, Marie Jose and Zindel, Daniel and Coudevylle, Nicolas and Riek, Roland and Orts, Julien},
title = {N MR 2 -Based Drug Discovery Pipeline Presented on the Oncogenic Protein KRAS},
journal = {Journal of the American Chemical Society},
year = {2025},
doi = {10.1021/jacs.4c16762}
}
EUVIMED